Harrow (HROW) Common Equity (2010 - 2026)
Harrow's (HROW) quarterly Common Equity came in at $28.7 million in Q1 2026, down 48.83% year-on-year from $56.1 million in Q1 2025, and down 44.89% quarter-over-quarter from $52.1 million in Q4 2025.
Harrow (HROW) Common Equity (2010 - 2026) Analysis & Trends
Harrow's Common Equity history runs 17 years deep, the most recent figure standing at $28.7 million for Q1 2026.
- On a quarterly basis, Common Equity fell 48.83% year-over-year to $28.7 million in Q1 2026; TTM through Mar 2026 was $28.7 million, a 48.83% decrease from a year earlier, with the FY2025 full-year figure at $52.1 million, down 24.83% from the prior year.
- Common Equity slipped to $28.7 million in Q1 2026 per HROW's latest filing, from $52.1 million in the prior quarter.
- Across five years, Common Equity topped out at $75.4 million in Q3 2023 and bottomed at $862000.0 in Q3 2022.
- The 5-year median for Common Equity is $49.3 million (2025), against an average of $41.8 million.
- Across the five-year window, Common Equity slumped 94.69% in 2022 and surged 8647.33% in 2023, its largest moves.
- Year by year, Common Equity stood at $27.2 million in 2022, then surged by 158.48% to $70.4 million in 2023, then decreased by 1.58% to $69.3 million in 2024, then declined by 24.83% to $52.1 million in 2025, then sank by 44.89% to $28.7 million in 2026.
- Per Business Quant, the three latest HROW Common Equity figures stand at $28.7 million (Q1 2026), $52.1 million (Q4 2025), and $47.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 28.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.71 Mn |
| Dec 31, 2025 | 52.09 Mn |
| Sep 30, 2025 | 47.02 Mn |
| Jun 30, 2025 | 49.30 Mn |
| Mar 31, 2025 | 56.10 Mn |
| Dec 31, 2024 | 69.30 Mn |
| Sep 30, 2024 | 57.62 Mn |
| Jun 30, 2024 | 58.18 Mn |
| Mar 31, 2024 | 60.21 Mn |
| Dec 31, 2023 | 70.41 Mn |
| Sep 30, 2023 | 75.40 Mn |
| Jun 30, 2023 | 22.05 Mn |
| Mar 31, 2023 | 21.53 Mn |
| Dec 31, 2022 | 27.24 Mn |
| Sep 30, 2022 | 862,000.00 |
| Jun 30, 2022 | 5.39 Mn |
| Mar 31, 2022 | 9.74 Mn |
| Dec 31, 2021 | 10.93 Mn |
| Sep 30, 2021 | 16.23 Mn |
| Jun 30, 2021 | 22.85 Mn |